Navigation Links
FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Date:10/28/2010

are overweight with co-morbidities. Obesity is a chronic condition defined by having excess body fat. Obesity significantly increases the risk of developing many different diseases and health conditions, including type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, some cancers and osteoarthritis. According to a report in The Lancet in 2009, morbid obesity shortens life expectancy by approximately 10 years, and moderate obesity shortens it by approximately 3 years.

Beyond its impact on health, obesity accounts for 9.1% of US annual health care spending – nearly $150 billion. By 2030, if trends in the escalating rates of obesity continue, healthcare costs attributable to obesity may reach $956 billion, accounting for up to 18% of total health care costs or $1 of every $6 spent on health care.

In August of this year, the CDC called attention to the "major public health problem" of obesity by issuing a national report citing the lack of progress against goals established 10 years ago by the federal government. The agency reported that all 50 states failed to meet the "Healthy People 2010" goal of lowering the obesity rate to 15%, and some states actually reported a significant increase in obesity rates. The agency includes obesity among six areas of focus in its "Winnable Battles" campaign to identify strategies, resources and partnerships to accelerate a measurable impact on health.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , 28 luglio 2014 ResMed (NYSE: ... di prodotti per la cura dei disturbi respiratori del ... ha avuto un,ingiunzione permanente in Germania contro il produttore ... proibisce la vendita di apparecchiature da indossare in testa, ... e le maschere 220. La sentenza della Corte Regionale ...
(Date:7/28/2014)... 2014   Cardioxyl Pharmaceuticals, Inc. announced today ... CXL-1427, a novel potential treatment for acute decompensated heart ... company has now initiated dosing of hospitalized patients with ... designed to further evaluate the drug,s safety and tolerability ... Phase I clinical trial evaluated the safety and tolerability ...
(Date:7/28/2014)... CLARA, Calif. , July 28, 2014  ProteinSimple ... assay for the Simple Western. This new assay allows users ... For the first time, Simple Western users can analyze ... The Simple Western has changed protein analysis as ... hassles of Western blot protocols - no messy gels, ...
Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2ProteinSimple Says "Never Run a Gel Again!" 2
... California Cryobank (CCB), the nation,s leading ... branch in Indianapolis, IN.  In conjunction with General ... York, Cambridge, and Palo Alto as California Cryobank,s sixth ... HCLD(ABB), and John Critser, PhD., General BioTech is a ...
... with active moderate to severe rheumatoid arthritis (RA) inadequately ... (Humira ® ) and who were actively switched to ... at week 10, and sustained response through week 26 ... from the RESTART study were presented for the first ...
Cached Medicine Technology:Nation's Leading Sperm Bank Opens Branch in Indianapolis, IN 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7
(Date:7/28/2014)... St. Jude Children’s Research Hospital has ... Defense Employer Support Freedom Award from the Employer Support of ... The award is the highest honor given by the U.S. ... serve in the National Guard and Reserve. , “We deeply ... contributions to the St. Jude mission and to our country,” ...
(Date:7/28/2014)... 2014...Mothers who live near green spaces deliver babies ... new study, "Green Spaces and Adverse Pregnancy Outcomes" ... Medicine . , A team of researchers from ... Negev (BGU), evaluated nearly 40,000 single live births ... Israel to determine the impact of green surroundings ...
(Date:7/28/2014)... HIV research findings made possible by a test developed ... Pharmaceutical Sciences (CU School of Pharmacy), AURORA, Colo (July 28, ... in the Colorado Antiviral Pharmacology Laboratory at the CU ... HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), ... , A study presented during the AIDS 2014 ...
(Date:7/28/2014)... Modesto, CA (PRWEB) July 28, 2014 At ... an uncomfortable situation where they’re forced to contact the authorities. ... little more difficult than it initially seems. , Not every ... a vehicle get stolen, a person get mugged, or a ... little less obvious, leading onlookers to be more passive than ...
(Date:7/28/2014)... The report “Industrial Enzymes Market ... Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & Geography ... and segments the global industrial enzymes market with ... industrial enzymes. It also identifies driving and restraining ... analysis of trends, opportunities, burning issues, winning imperatives, ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4
... of a particular drug than the individual effect of both the ... where the avian bird flu is posing a serious threat across ... is a prescribed drug for seasonal flu, because it will be ... in Asia and reported in other areas mutates into a human ...
... have been implicated in a number of human ... pox, measles, rubella, polio, hepatitis, warts, influenza, common ... have now //,reported that a potentially life threatening ... population. ,The findings...indicate the possible presence ...
... Carskadon from Bradley Hospital Sleep Laboratory, Brown University has found ... to bed late. Study has found that teens are not ... they get up early in the morning resulting in a ... in the Journal American Academy of Sleep Medicine. ...
... US and University of Tokyo, Japan have found a faster ... a bird flu outbreak involving mutant strain of virus occurs. ... the avian virus which may be very lethal and may ... University of Wisconsin-Madison, working with Japanese colleagues from the University ...
... more likely to occur in patients who take high ... safety profile of non-steroidal anti-inflammatory drugs (NSAIDs). // Furthermore, ... days after starting an ibuprofen regimen. ... favorable safety profiles of all of the traditional non-selective ...
... of India has today assured that there was no real ... // ,The government has set up a nationwide ... the domestic poultry population and migratory birds and to constantly ... as and when required. ,"We are keeping a ...
Cached Medicine News:Health News:Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid 2Health News:Reports of Hantavirus infection in India raise concerns 2Health News:Faster way of producing Bird flu vaccine using Reverse Genetics 2
Triad Plus PVP-I Scrub Winged Sponges...
Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
Medicine Products: